Search Results

biotech company with a unique portfolio of CB1 inverse agonists, today announces the appointment of Glenn S. Vraniak to the position of Chief Financial Officer (CFO), effective immediately. Mr. Vraniak’s career spans more than 20 years of financial and commercial experience in the life sciences Vraniak served as Chief Financial Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company

Here we report that neuropeptide S (NPS) signaling in the PVT is necessary for stimulus salience encoding

November 2021 Read more at the source #DrGPCR #GPCR #IndustryNews

<< Back to podcast list Strategic Partner(s) Tanishka S. Saraf About Tanishka S. neurobiology of neuropsychiatric disorders and to develop safe and effective treatments. " Tanishka S.

<< Back to podcast list Strategic Partner(s) Dr. Roger Sunahara About Dr. G protein splice forms, specifically the short and long forms of the stimulatory G protein, Galpha-s( s) and Galpha-s(l), respectively. We demonstrated that Galpha-s(l), but not Galpha-s(s), regulates extracellularly regulated kinases (ERK We speculate that these aberrations in Galpha-s(l), specifically, may be involved in other pathologies

<< Back to podcast list Strategic Partner(s) Dr. Richard Premont About Dr. Richard Premont "Dr. Harrington Discovery Institute and Case Western Reserve University, where he studies GPCR regulation by S-nitrosylation by GIT/PIX scaffolding complexes during cellular signaling, and characterizing the role of protein S-nitrosylation